Cambridge, UK, 02 October 2024: Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop eProtein Discovery™ system, announces key leadership changes, including Dr Gordon McInroy’s promotion to the role of Chief Operating Officer, Dr Tobias Ost moves to become Senior Vice President Product Development and Charu Maini will take the role of Senior Vice President of People. Following a pivotal year for the Company, including the commercial launch of the eProtein Discovery system, these appointments demonstrate Nuclera’s continued focus on scaling the business and driving technological innovation to advance protein production within research labs.
Gordon, a co-founder of Nuclera and formerly Chief Technical Officer at the Company, was instrumental in establishing the company and leading development of eProtein Discovery in preparation for the commercial launch earlier this year. While founding Nuclera in 2013, Gordon was a postdoctoral research associate and completed his PhD in Chemistry at the University of Cambridge. Gordon holds a Masters in Natural Science from the University of Cambridge.
Tobias, previously Vice President of Research and Development of Nuclera, has played a key role in innovating product development at the company. With over 20 years’ experience of life science tools development, Tobias has held senior leadership roles in companies including Solexa, Cambridge Epigenetix (now biomodal), and DNAe and field applications roles, supporting customers and building support teams, at Illumina and Pacific Biosciences. Tobias has a PhD in Enzymology and Bioinorganic Chemistry and a BSc (Hons) in Chemistry from the University of Edinburgh.
Charu, previously Vice President of People of Nuclera, has played a crucial role in driving leadership development and talent acquisition. During this time, Charu was instrumental in building a performance culture, doubling Nuclera's headcount and implementing HR programs such as stock incentive plans and an enhanced pension plan. Charu brings extensive experience in leading global HR activities and developing people programs, including for Microsoft, American Express and PricewaterhouseCoopers to Nuclera.
Dr Gordon McInroy, COO and co-founder, Nuclera commented: “It has been a privilege to have been involved with Nuclera since the Company was founded. Now, as we transition into our commercial growth phase, I am excited to continue to support Michael and the executive leadership team with business operations by streamlining processes and continuing to build our culture of quality and delivery. I will also focus on supporting and developing our team as we continue to build new products that overcome the protein inaccessibility bottleneck.”
Dr Tobias Ost, SVP Product Development, Nuclera added: “I am looking forward to this new role where I will be able to improve work processes and provide strategic direction to support product success. I am especially keen to support new innovation for eProtein Discovery, to ensure we continue to deliver products which solve customers’ problems by enabling them to produce the proteins they need.”
Charu Maini, SVP of People commented: “It’s been exciting to be part of Nuclera’s journey over the past few years. I continue to look forward to the tremendous opportunity to shape the culture, support growth, and create a positive impact across the organization. I am grateful to my colleagues for being part of this journey and for making our workplace a vibrant, inspiring place to be.”
Dr Michael Chen, CEO and co-founder, Nuclera, said: “These three appointments underline our focus on the efficient execution of the Company’s long-term goals. Appointing Gordon as our first Chief Operating Officer is an essential step in Nuclera’s commercial journey and will be key to meeting our goal of enhancing protein access. Tobias’ role of SVP of Product Development will ensure that our product offerings continue to consistently meet market demands and customer needs. Charu’s position as SVP People will be essential to ensuring our people agenda continues to be developed as we scale the company.”
For more information about Nuclera’s eProtein Discovery system, please visit: https://www.nuclera.com/system/
